New Test Developed For Early Detection Of Lyme Disease
By LabMedica International staff writers Posted on 12 May 2016 |

Image: A dark field photomicrography reveals the presence of spirochete, or “corkscrew-shaped” bacteria known as Borrelia spp., which is the pathogen responsible for causing Lyme disease (Photo courtesy of Jeffrey Nelson).
A new test for early detection of Lyme disease (borreliosis) is being developed and this will improve the ability to detect an active infection more easily than before so that healthy people with Lyme disease antibodies in their blood do not receive unnecessary antibiotic treatment and so that appropriate treatments can be initiated at an early stage.
The current test is only able to analyze part of the human immune system, namely the B-cells but not the T-cells, which are needed as helper cells to fight the infection and whose activity indicates the presence of an infection. The antibody tests that are currently available only provide a reliable result three to four weeks after infection has occurred.
Immunologists at the Medical University of Vienna (Austria) are developing the world's first point-of-care test, which could be used to detect an active infection so that patients could start the appropriate treatment. The test, which is known as the "Ixodes Kit" should be in clinical use in the autumn of 2016, said the scientists, speaking on the occasion of World Immunology Day 2016. Ixodes is the scientific name for hard-bodied ticks that transmit the disease.
Lyme disease is particularly common in Central Europe and in the Scandinavian countries. As a result of climate change, its area of spread is continuously moving northwards. Tick activity is starting earlier and earlier. In Austria itself, they currently have the best climate for ticks. Every year around 70,000 people in Austria develop Lyme disease after being bitten by a deer tick. Approximately one in every four ticks carries Lyme disease. So-called erythema migrans is a sure sign of infection with tick-borne Lyme disease. However, this only occurs in around one third of patients. If the bacterial infection is not detected in good time it can lead to serious problems such as joint inflammation and even very painful infections of the nerve roots resulting in paralysis or memory loss.
Hannes Stockinger, PhD, a professor and Head of the Institute for Hygiene and Applied Immunology, said, “Unfortunately, the current standard laboratory test is often unable to detect Lyme disease at an early stage of the infection. On top of that, the current test often interprets a mere antibody reaction as an infection and people are treated with antibiotics unnecessarily, because the infection is way in the past or is already completely resolved.” In Europe and Asia, the bacteria Borrelia afzelii and Borrelia garinii are the causes of Lyme disease.
Related Links:
Medical University of Vienna
The current test is only able to analyze part of the human immune system, namely the B-cells but not the T-cells, which are needed as helper cells to fight the infection and whose activity indicates the presence of an infection. The antibody tests that are currently available only provide a reliable result three to four weeks after infection has occurred.
Immunologists at the Medical University of Vienna (Austria) are developing the world's first point-of-care test, which could be used to detect an active infection so that patients could start the appropriate treatment. The test, which is known as the "Ixodes Kit" should be in clinical use in the autumn of 2016, said the scientists, speaking on the occasion of World Immunology Day 2016. Ixodes is the scientific name for hard-bodied ticks that transmit the disease.
Lyme disease is particularly common in Central Europe and in the Scandinavian countries. As a result of climate change, its area of spread is continuously moving northwards. Tick activity is starting earlier and earlier. In Austria itself, they currently have the best climate for ticks. Every year around 70,000 people in Austria develop Lyme disease after being bitten by a deer tick. Approximately one in every four ticks carries Lyme disease. So-called erythema migrans is a sure sign of infection with tick-borne Lyme disease. However, this only occurs in around one third of patients. If the bacterial infection is not detected in good time it can lead to serious problems such as joint inflammation and even very painful infections of the nerve roots resulting in paralysis or memory loss.
Hannes Stockinger, PhD, a professor and Head of the Institute for Hygiene and Applied Immunology, said, “Unfortunately, the current standard laboratory test is often unable to detect Lyme disease at an early stage of the infection. On top of that, the current test often interprets a mere antibody reaction as an infection and people are treated with antibiotics unnecessarily, because the infection is way in the past or is already completely resolved.” In Europe and Asia, the bacteria Borrelia afzelii and Borrelia garinii are the causes of Lyme disease.
Related Links:
Medical University of Vienna
Latest Immunology News
- Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer
- Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes
- World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment
- Blood Test Detects Organ Rejection in Heart Transplant Patients
- Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
- Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
- New Tool Detects Breast Cancer Relapses Five Years in Advance
- T Cells in Blood Can Detect Parkinson's Years Before Diagnosis
- POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood
- Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients
- First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreMolecular Diagnostics
view channel
New Biomarker Panel to Enable Early Detection of Pancreatic Cancer
Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more
Ultrarapid Whole Genome Sequencing for Neonatal and Pediatric Patients Delivers Results In 48 Hours
Genetic diseases are the leading identifiable cause of infant mortality, and early diagnosis is crucial to improve patient outcomes. In the neonatal and pediatric intensive care units (NICU and PICU),... Read more
AI-Enabled Blood Test Demonstrates Diagnostic, Prognostic and Predictive Utility Across Cancer Continuum
Cancer remains a major challenge in healthcare due to difficulties in early detection and accurate diagnosis. Many cancers are diagnosed at advanced stages, limiting treatment options and impacting survival rates.... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer
Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more
Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes
Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read morePathology
view channel
AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care
Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
AI Tool Enhances Interpretation of Tissue Samples by Pathologists
Malignant melanoma, a form of skin cancer, is diagnosed by pathologists based on tissue samples. A crucial aspect of this process is estimating the presence of tumor-infiltrating lymphocytes (TILs), immune... Read more
AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
Hepatocellular carcinoma (HCC), a common type of liver cancer, is difficult to diagnose early and accurately due to the limitations of current diagnostic methods. Glycans, carbohydrate structures present... Read moreTechnology
view channel
Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation
Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Ultra-Sensitive Biosensor Based on Light and AI Enables Early Cancer Diagnosis
Cancer diagnosis is often delayed due to the difficulty in detecting early-stage cancer markers. In particular, the concentration of methylated DNA in the bloodstream during the early stages of cancer... Read moreIndustry
view channel
2025 COMPAMED Innovation Forum Highlights Pioneering Work in Cancer Diagnostics
Cancer cases are among the biggest challenges faced by global healthcare systems. The incidence has risen in recent decades, not least on account of demographic change and escalating risk factors.... Read more
Quanterix Completes Acquisition of Akoya Biosciences
Quanterix Corporation (Billerica, MA, USA) has completed its previously announced acquisition of Akoya Biosciences (Marlborough, MA, USA), paving the way for the creation of the first integrated solution... Read more
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. In conjunction with... Read more